Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1390&sort=end_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=end_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=end_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=end_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1389&sort=end_date" }, "data": [ { "type": "Grant", "id": "14704", "attributes": { "award_id": "1K23EY035741-01", "title": "Artificial Intelligence Analysis of Myopic Vitreoretinal Pathology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Eye Institute (NEI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31398, "first_name": "EDWIN C", "last_name": "Clayton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-01", "end_date": "2029-02-28", "award_amount": 274148, "principal_investigator": { "id": 31399, "first_name": "Cassie Ann", "last_name": "Ludwig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY: This application seeks a career development award for an academic vitreoretinal surgeon with an interest in high myopia, a condition which predisposes patients to potentially blinding complications including retinal tears (RTs) and rhegmatogenous retinal detachments (RRDs). This proposal is a 5-year curriculum and research plan to transition Dr. Cassie Ludwig to independence. The candidate is an accomplished early career physician-scientist who will undergo all training and execute the research noted herein during this period. Myopia affects one third of the world's population today and has been predicted to affect 50% of the world's population by 2050.1,2 Worse, this prediction is likely an underestimate as myopigenic behaviors have been further compounded by the COVID pandemic and digital remote learning.3–8 This increasing prevalence has significant consequences as each diopter of myopia increases the risk of retinal tears and detachments, myopic macular degeneration, choroidal neovascularization, myopic traction maculopathy, strabismus, glaucoma, and cataracts. Slowing myopia progression even minimally can help prevent blindness. Using combined data from five large population-based studies, Bullimore et al. found that slowing myopia by one diopter should reduce the likelihood of a patient developing an RRD by 30%.2 Electronic health records (EHRs) and ophthalmic imaging databases contain enormous quantities of systemic and ocular data generated by clinical practice which can be used to better understand the relationship between systemic and ophthalmic risk factors, myopia and RTs and RRDs. EHR and imaging data can be fused into predictive models that employ machine learning to risk-stratify patients. In this proposal, Dr. Ludwig aims to achieve the following: 1. Develop and validate a structured EHR deep learning framework to predict RT and RRD risk in myopes and non-myopes 2. Develop and validate an unstructured EHR transformer-based deep learning model to predict RT and RRD risk in myopes and non-myopes, and 3. Develop and validate an ultra-widefield photography convolutional neural network (CNN)-based deep learning model to predict RT and RRD risk in myopes and non-myopes. The central hypothesis is that modeling of attributes from EHR data and images can predict risk of RTs and RRDs. The principal investigator, Cassie A. Ludwig, MD, MS, will perform this research as part of a larger effort to obtain additional training and mentorship in biomedical informatics, artificial intelligence, biodesign, and myopia. Dr. Ludwig’s career development plan includes a PhD program with didactic coursework, conferences, workshops, and frequent communication and interaction with a network of mentors with an impressive abundance of their own NIH funding and prior mentorship experiences. This experience will guide Dr. Ludwig into a career as an independent clinician-scientist with expertise in artificial intelligence and a focus on myopia and its sequelae.", "keywords": [ "Affect", "Algorithms", "Artificial Intelligence", "Behavior", "Bioinformatics", "Blindness", "COVID-19 pandemic", "Cataract", "Choroidal Neovascularization", "Clinical", "Code", "Color", "Communication", "Cornea", "Data", "Databases", "Development Plans", "Diabetic Retinopathy", "Diagnosis", "Disease", "Distance Learning", "Doctor of Philosophy", "Educational Curriculum", "Educational workshop", "Electronic Health Record", "Faculty", "Funding", "Fundus photography", "Glaucoma", "Goals", "Image", "K-Series Research Career Programs", "Knowledge", "Length", "Light", "Link", "Logistic Regressions", "Machine Learning", "Macular degeneration", "Mentors", "Mentorship", "Methodology", "Methods", "Modeling", "Myopia", "Natural Language Processing", "Optical Coherence Tomography", "Outcome", "Pathologic", "Pathology", "Patients", "Photography", "Physicians", "Population", "Population Study", "Prevalence", "Prevention", "Principal Investigator", "Prophylactic treatment", "Provider", "Radiology Specialty", "Reporting", "Research", "Retina", "Retinal Detachment", "Retinal Diseases", "Retinal Perforations", "Risk", "Risk Factors", "Scientist", "Sensitivity and Specificity", "Statistical Methods", "Strabismus", "Structure", "Surgeon", "Symptoms", "Testing", "Text", "Thick", "Traction", "Training", "United States National Institutes of Health", "Validation", "Vision", "Visual", "artificial intelligence algorithm", "biomedical informatics", "career", "career development", "clinical encounter", "clinical practice", "cohort", "convolutional neural network", "deep learning", "deep learning model", "deep neural network", "demographics", "digital", "disorder of macula of retina", "electronic structure", "experience", "high risk", "improved", "interest", "machine learning model", "ophthalmic examination", "patient stratification", "predictive modeling", "prevent", "programs", "prophylactic", "repaired", "retinal imaging", "risk prediction", "risk stratification", "standard of care", "symposium", "training opportunity", "vitreous floater" ], "approved": true } }, { "type": "Grant", "id": "14708", "attributes": { "award_id": "1U01AI179524-01", "title": "Systems analyses of induction and maintenance of immunity to SARS-CoV-2 vaccination in kidney transplant recipients receiving mycophenolate mofetil immunotherapy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6717, "first_name": "Conrad M.", "last_name": "Mallia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-01", "end_date": "2029-02-28", "award_amount": 605731, "principal_investigator": { "id": 23198, "first_name": "ELAINE F", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Immunocompromised patients, including those requiring immunosuppressive therapy following organ transplantation, are at high risk for severe disease from SARS‐CoV‐2. As SARS-CoV-2 rapidly transitions from a pandemic virus to endemic status, like influenza, seasonal vaccinations against emerging variants will likely become the primary tool for limiting morbidity and mortality. While the efficacy of vaccination against SARS-CoV- 2 has been very promising, specific populations have been identified who are at increased risk of failing to develop protective immunity. Immunocompromised populations respond poorly to SARS-CoV-2 vaccination, particularly solid organ transplant (SOT) recipients receiving immunosuppressive therapy. Within SOT recipients, the type and dose of immunosuppressive therapy have further been shown to impact vaccine efficacy. Patients receiving mycophenolate mofetil (MMF) immunotherapy, which functions by preventing B and T cell proliferation/activation, as well as leukocyte recruitment, have the poorest humoral and cellular response post- vaccination for SARS-CoV-2. Preliminary evidence suggests that discontinuing MMF before vaccination improves humoral responses in SOT recipients. This project will test the hypothesis that coordinated innate and adaptive dysregulation pre-vaccination driven by MMF immunosuppressive therapy diminishes the quality, quantity, and durability of cellular and humoral immunity to SARS-CoV-2 in kidney transplant recipients. In Aim 1, we will characterize the impact of MMF on the generation, quality, and maintenance of adaptive immune responses to SARS-CoV-2 vaccination in SOT recipients. We will use validated assays to quantify and functionally profile humoral and cellular immunity to SARS-CoV-2. In Aim 2, we will define the pre-vaccine immunological determinants of a protective host immune response to SARS-CoV-2 vaccination in kidney transplant recipients and identify the mechanisms of MMF-diminished immunity. We will use systems biological tools to comprehensively profile, at the single-cell level, the peripheral immune system prior to vaccination. In Aim 3, we will determine how pre-vaccine MMF reduction impacts the host immune response to SARS-CoV-2 booster vaccination in kidney transplant recipients. Together, these data will provide a comprehensive, mechanistic understanding of how MMF immunotherapy dysregulates the immune system in SOT recipients and how this dysregulation impacts the induction and durability of protective immunity against SARS-CoV-2. This knowledge will allow the development of targeted strategies to correct or circumvent MMF-driven immune dysregulation, thereby permitting efficacious responses to SARS-CoV-2, and other vaccines, in SOT recipients and other at-risk populations.", "keywords": [ "2019-nCoV", "Acute", "Address", "Antibodies", "Antibody titer measurement", "B-Lymphocytes", "Biological Assay", "COVID-19 booster", "COVID-19 vaccination", "Cells", "Cellular Immunity", "Clinical", "Clinical Trials", "Computer Models", "DNA Methylation", "Data", "Development", "Disease", "Dose", "Effectiveness", "Enrollment", "General Population", "Generations", "Goals", "Humoral Immunities", "Immune", "Immune System Diseases", "Immune response", "Immune system", "Immunity", "Immunocompromised Host", "Immunologics", "Immunosuppressive Agents", "Immunotherapy", "Impairment", "Individual", "Infection", "Influenza", "Kidney Transplantation", "Knowledge", "Leukocytes", "Maintenance", "Methods", "Morbidity - disease rate", "Organ Transplantation", "Patients", "Peripheral", "Peripheral Blood Mononuclear Cell", "Persons", "Pharmaceutical Preparations", "Phase", "Plasma", "Population", "Populations at Risk", "Research", "Risk", "SARS-CoV-2 antibody", "SARS-CoV-2 immunity", "Seasons", "Secondary Immunization", "Severe Acute Respiratory Syndrome", "Solid", "Systems Analysis", "T cell response", "T-Cell Proliferation", "Testing", "Therapeutic immunosuppression", "Transplant Recipients", "Vaccination", "Vaccines", "Variant", "Virus", "adaptive immune response", "biological systems", "high risk", "improved", "methylation pattern", "mortality", "mycophenolate mofetil", "organ transplant recipient", "pandemic disease", "pandemic virus", "prediction algorithm", "predictive signature", "prevent", "recruit", "response", "tool", "vaccination strategy", "vaccine efficacy", "vaccine response" ], "approved": true } }, { "type": "Grant", "id": "14816", "attributes": { "award_id": "1R01HL173537-01", "title": "An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23102, "first_name": "Aruna R.", "last_name": "Natarajan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-01", "end_date": "2029-02-28", "award_amount": 694403, "principal_investigator": { "id": 31495, "first_name": "Joshua", "last_name": "Kennedy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1427, "ror": "", "name": "ARKANSAS CHILDREN'S HOSPITAL RES INST", "address": "", "city": "", "state": "AR", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory viral coinfections (RVCIs) are more common in children than adults and have become increasingly important due to the emergence of SARS-COV-2. However, the distinction between coinfection and codetection remains unclear. Further, the association between finding multiple viruses using our current clinical methods and the effect on clinical outcomes is nebulous. Understanding positive viral testing has become crucial with the ongoing spread of SARS-CoV-2 and the treatment algorithms that are expensive or deleterious to patients with other viruses. Currently, clinicians struggle to identify the dominant virus inducing the host immune response in RVCIs in children. Our group has developed gene classifiers to identify adults with SARS-CoV-2 compared to other viruses using nasopharyngeal swabs. Further, we are the first to develop a host/microbe classifier for pediatric patients on the ventilator that will distinguish lower respiratory tract infections using lower airway sampling. Here, our objective is to identify patient features, coinfecting viruses, microbial contributions, and host responses that enhance disease severity in SARS-CoV-2–infected children. As the only pediatric hospital in the state, Arkansas Children's Hospital is an ideal site for studying SARS-CoV-2 RVCIs. We aim to leverage our unique multi-institutional collaborative team with extensive experience applying metagenomic next-generation sequencing to simultaneously evaluate viral and host genetic material from clinically obtained nasopharyngeal specimens. This approach identifies host–virus interactions and allows us to assess their impact on immune responses and disease severity during RVCIs. We hypothesize that a combination of patient characteristics, viral features, and host immune responses will predispose a child to more severe disease. We also expect to identify an immunologic fingerprint for SARS-CoV-2 that can be used to identify it as the “infecting virus” in children with codetections. The impact of this study is significant, and the multidisciplinary team that this proposal brings together is experienced. By employing epidemiologic, -omic, and computational approaches, we will identify immunologic fingerprints of SARS-CoV-2 infections in children, which can help identify the “infecting virus” when multiple viruses are detected. Further, this study will provide distinction regarding the clinical implications of codetections of viruses, including SARS-CoV-2, in children. The findings will support future clinical trials evaluating treatment options based on the immunologic fingerprints that we identify.", "keywords": [ "2019-nCoV", "5 year old", "Acute respiratory infection", "Adult", "Affect", "Age", "Algorithms", "Area Under Curve", "Arkansas", "COVID-19 treatment", "Characteristics", "Child", "Clinical", "Clinical Trials", "Data", "Disease", "Enterovirus", "Epidemiology", "Ethnic Origin", "Fingerprint", "Future", "Gender", "Gene Expression", "Genes", "Genetic Materials", "Immune System Diseases", "Immune response", "Immunologics", "Immunomodulators", "Individual", "Infection", "Institution", "Knowledge", "Laboratories", "Lower Respiratory Tract Infection", "Metagenomics", "Methods", "Microbe", "Modeling", "Monoclonal Antibodies", "Nasopharynx", "Outcome", "Pathogenicity", "Patients", "Pediatric Hospitals", "Prevention", "Prognosis", "Race", "Recording of previous events", "Research Personnel", "Respiratory Syncytial Virus Infections", "Respiratory syncytial virus", "Rhinovirus", "Risk", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sampling", "Severe Acute Respiratory Syndrome", "Severities", "Severity of illness", "Site", "Specimen", "Steroids", "Symptoms", "Testing", "Vaccination", "Ventilator", "Viral", "Virus", "Virus Diseases", "World Health Organization", "clinical material", "co-infection", "comorbidity", "experience", "improved", "improved outcome", "interest", "microbial", "multidisciplinary", "nasopharyngeal swab", "next generation sequencing", "novel", "pathogenic microbe", "pediatric patients", "pediatrician", "predictive modeling", "respiratory", "respiratory pathogen", "severe COVID-19", "targeted therapy trials", "targeted treatment", "tocilizumab", "viral detection", "virus host interaction", "virus testing" ], "approved": true } }, { "type": "Grant", "id": "14899", "attributes": { "award_id": "1R01AG083464-01A1", "title": "Identifying salient factors that influence physician practices in mitigating patient misinformation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8342, "first_name": "Marcel", "last_name": "Salive", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-15", "end_date": "2029-02-28", "award_amount": 729380, "principal_investigator": { "id": 31587, "first_name": "Zubin", "last_name": "Master", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1149, "ror": "", "name": "WAKE FOREST UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Medical misinformation is a global health problem with 73% of US adults having been exposed to false health information and 87% expressing concern about it. Health misinformation can hijack a patient’s typical discernment faculties and can lead to poor health outcomes. Evidence shows that elderly patients are disproportionately affected by health misinformation and are more likely to believe and spread misinformation, and suffer negative consequences. Engaging physicians has been touted as a promising and plausible means to mitigate misinformation because they are highly trusted, routinely provide reliable medical information, and are effective at influencing sustainable behavior change. Yet there is virtually no empirical data about physician misinformation corrective practices. Physician practices to correct patient misinformation is likely to depend on their political and religious beliefs as seen in other health areas, familiarity with the topic, correction and communication skills, self-efficacy, and environmental (e.g., time) and interpersonal factors (e.g., exhaustion). Prior to developing scalable and evidence-based physician communication interventions, a rich assessment of factors that facilitate or impede physician corrective practices is needed. We use a mixed-methods approach to identify factors and the strength of association among barriers/facilitators and physician willingness to correct misinformation through three specific aims using two divergent cases: unproven stem cell therapies and Covid- 19 vaccination. In Aim 1, we will interview primary care physicians to assess knowledge, experience, attitudes, and beliefs about correcting misinformation. In Aim 2, we will create a novel Determinants of Willingness to Correct Misinformation (DWCM) measure based on Aim 1 qualitative data, expert review, cognitive interviews, and psychometrically evaluate dimensionality and internal consistency. A national survey of physicians using the validated DWCM instrument will be conducted to measure determinants that impact physician corrective practices and attitudes towards adopting a priori correction strategies in their practice. In Aim 3, we will conduct online asynchronous focus groups with elderly patients across the US to assess receptivity towards corrective information from physicians, communication comprehension, channel preferences, and affect towards receiving corrective information and the use of specific terminology. Upon completing this research, we will have (i) identified major factors and their association with physician misinformation corrective practices and their attitudes towards adopting corrective strategies; (ii) created a valid DWCM climate instrument that can be deployed in different health care environments; (iii) offered data into patient receptivity towards receiving corrective information from physicians, including modes of exchange and appropriate language, and (iv) be well-positioned to develop and test the efficacy of a misinformation correction toolkit for physicians in future research.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15264", "attributes": { "award_id": "1R01MD019749-01", "title": "Motivate, Vaccinate, Activate’: An effectiveness-implementation trial to assess the impact of a multi-component community-based intervention to increase RSV vaccine uptake among Latino older adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-26", "end_date": "2029-02-28", "award_amount": 686134, "principal_investigator": { "id": 31852, "first_name": "Carina", "last_name": "Marquez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory Syncytial Virus (RSV) causes a substantial burden of hospitalizations and deaths among older adults, comparable to that of influenza. The new and effective RSV vaccines have the potential to dramatically reduce RSV morbidity and mortality, yet their full public health impact will not be realized if the racial and ethnic disparities in RSV vaccine uptake mirror those observed in other respiratory virus-vaccines, from COVID-19 to influenza. We have the opportunity to adapt community-based interventions from the COVID-19 pandemic to proactively address disparities in RSV vaccine uptake. However, evidence-based data, conducted in partnership with impacted communities, are essential. This project will focus on increasing RSV vaccine uptake among Latinos, a community disproportionatly affected by respiratory vaccines and RSV. We will leverage our well-established community-academic partnership, Unidos en Salud, to adapt two components of our ‘Motivate, Vaccinate, Activate’ intervention— CHW counseling and text message nudges. This multi-component intervention was originally designed to increase COVID-19 vaccine uptake among Latinos and to activate people to recommend vaccination to people in one’s social network. Our overall study objective is to adapt this intervention to inform effective and customizable community-based strategies to increase RSV vaccine uptake. In addition to a rigorous randomized trial design, we will collect detailed implementation outcomes to aide in generalizability and adaption to other vaccines and settings. Our primary hypothesis is that language-and culturally-concordant CHW motivation and activation counseling sessions, coupled with text message nudges, will increase RSV vaccine confidence by adressing trust, knowledge, and access-related barriers. The proposed study has three aims. In Aim 1 we will use the ADAPT-IT framework to adapt two intervention components: CHW counseling and text-message nudges to increase RSV vaccine uptake among Latino older adults (>60 years) (Aim 1a) and enable younger adults (18-50 years old) to discuss RSV vaccination with older adults in their social and family networks (Aim 1b). Then in Aim 2 we will conduct a two-arm type-1 effectiveness implementation trial to determine the effectiveness and implementation of a CHW counseling and text-message intervention on RSV vaccine uptake in Latino adults >60 years. In Aim 3, using a parallel trial design and social network analytic techniques, we will test the effectiveness of CHW counseling and text-message nudges on activating Latino adults to discuss RSV vaccination with the older adults within their social networks. The proposed work will provide timely, rigorous, and adaptable data to directly inform community-based approaches to increase RSV vaccination. In addition to providing timely data to reduce RSV vaccine disparities, these data will also advance our scientific understanding of the effectiveness of text-messages from community-based organizations and community-based interventions aimed at activating cross-generational social networks to boost vaccine uptake.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15608", "attributes": { "award_id": "1R01EB037025-01", "title": "Synthetic RNA Switch-Based Temporal and Dose Control of in Vivo Gene Therapies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 28204, "first_name": "NICHOLE MARIE", "last_name": "Daringer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": "2029-02-28", "award_amount": 540524, "principal_investigator": { "id": 32104, "first_name": "Guocai", "last_name": "Zhong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "One-time in vivo gene therapies, based on adeno-associated viral (AAV) vector delivery of genes encoding therapeutic proteins, noncoding RNAs, or genome/epigenome editors, may provide long-lasting (years of, or even lifelong) treatments or cures for many rare and common diseases. However, we cannot currently tune or inactivate transgene expression to reflect disease progression or the emergence of adverse events or contraindications over time, limiting the utility of AAV gene therapies. The constrained packaging capacity of AAV vectors (~4.7 kb) has thwarted development of genetic switches that can regulate transgene expression timing or levels—the solution to these limitations. To date, just a few AAV-compatible switches function in animals. Typically, these switches are activated or repressed by ligands with undesirable side effect, including rapamycin, a potent immune suppressant; tetracycline, an antibiotic not suitable for chronic use; and branaplam, a compound that causes peripheral neurotoxicity. We previously engineered an efficient synthetic RNA ON switch based on our novel self-cleaving ribozyme T3H38, which is regulated by a complementary morpholino oligonucleotide. At 63 bp long, the tiny T3H38 ribozyme can be inserted into the 3′ UTR of a transgene. Its regulator, a 25 nt morpholino oligo is part of a class of chemically modified RNA drugs that have proven safe for chronic use in humans. The T3H38 ribozyme showed a ~200-fold regulation in AAV transgene expression in mice upon administration of the complementary morpholino oligo to the animals. Optimizing the T3H38 ribozyme switch towards a leak-free system with no detectable baseline transgene expression in the absence of the morpholino oligo could transform AAV-based gene therapy. For example, it can enable safe use of AAV to express a variety of transgenes with narrow therapeutic windows (e.g., cytokines, hormones, genome editors), where an overdose or prolonged exposure can cause severe adverse events, or to conditionally express therapeutics with major contraindications (e.g., cytokines), specific disease conditions where a drug should not be used or should be discontinued. In preliminary studies, we have developed an enhanced RNA ON switch (regulatory range: up to 35,000-fold in mice) based on the T3H38 ribozyme. Here, we will (i) optimize the enhanced RNA switch to engineer an ultra-efficient switch with negligible leakiness; (ii) use the optimized switch for precise dose control of an AAV expressing erythropoietin—a paradigmatic biologic with a short half-life, a narrow therapeutic window, and major contraindications—for the treatment of chronic Epo-deficient anemia in a mouse model; and (iii) further optimize the switch system in mouse airways for temporal control of an AAV expressing a broadly anti-coronavirus immunoadhesin—a prototype of a broadly effective prophylaxis for immunocompromised individuals against a panel of coronaviruses of pandemic potential. The completion of this project will provide a broadly useful and potentially transformative regulatable gene therapy technology and proofs of concept showcasing the utility of this technology.", "keywords": [ "3&apos", "Untranslated Regions", "ACE2", "Adverse effects", "Adverse event", "Anemia", "Animals", "Antibiotics", "Biological", "Biological Products", "COVID-19", "Catalytic RNA", "Cell Culture Techniques", "Chemicals", "Chronic", "Circulation", "Communicable Diseases", "Coronavirus", "Development", "Devices", "Disease", "Disease Progression", "Dose", "Duchenne muscular dystrophy", "Ebola", "Engineering", "Episome", "Erythropoietin", "Friends", "Gene Delivery", "Gene Expression", "Genetic", "Genome", "Goals", "HIV Infections", "Half-Life", "Hormones", "Human", "Immune", "Immunocompromised Host", "Individual", "Interphase Cell", "Kinetics", "Ligands", "Luciferases", "Mediating", "Mus", "Muscle", "Oligonucleotides", "Overdose", "Peripheral", "Pharmaceutical Preparations", "Prophylactic treatment", "Proteins", "RNA", "Regulation", "Reporter", "Repression", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Safety", "Serious Adverse Event", "Sirolimus", "Somatic Cell", "System", "Technology", "Tetracyclines", "Therapeutic", "Time", "Transgenes", "Untranslated RNA", "Viral", "Viral Genes", "Viral Vector", "adeno-associated viral vector", "adenovirus mediated delivery", "cytokine", "epigenome", "expression vector", "feasibility testing", "gene therapy", "genome editor", "high risk population", "human disease", "improved", "in vivo", "mouse model", "neurotoxicity", "neutralizing antibody", "novel", "pandemic coronavirus", "prototype", "rare genetic disorder", "receptor", "side effect", "therapeutic protein", "transgene expression" ], "approved": true } }, { "type": "Grant", "id": "15685", "attributes": { "award_id": "1R01HL174310-01A1", "title": "Multi-scale characterization of antigen-polymerized immune complexes underlying thrombotic pathologies triggered by adenoviral-vectored vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32532, "first_name": "RONALD Q", "last_name": "WARREN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-05-01", "end_date": "2029-02-28", "award_amount": 601677, "principal_investigator": { "id": 32533, "first_name": "IGOR A", "last_name": "KALTASHOV", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 200, "ror": "https://ror.org/0072zz521", "name": "University of Massachusetts Amherst", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Immunothrombosis is a critical element of intravascular immunity, but its dysregulation or malfunction leads to a range of thrombotic disorders including stroke and disseminated intravascular coagulation. The massive vaccination campaign during the recent COVID-19 pandemic brought to light a novel immunothrombotic pathology, a relatively rare but extremely dangerous side effect of adenoviral (Ad) vectored vaccines, which is now known as vaccine-induced immune thrombotic thrombocytopenia (VITT). Although COVID-19 is no longer a global health threat, the close association of VITT with a specific delivery vector raises the specter of other Ad- vectored vaccines also eliciting this deadly side effect, a grave prospect given the popularity of this platform. VITT has been linked to the emergence of autoantibodies recognizing a cognate chemokine, platelet factor 4 (PF4), but the specific mechanism underlying this pathology remains elusive. Understanding its molecular mechanism and etiology is critical for addressing the currently unmet need to design rational therapeutic and prophylactic strategies targeting VITT. It will also go a long way towards filling the gaps in understanding the delicate interplay between the beneficial and deleterious effects of immunothrombosis and provide the urgently needed ammunition to suppress the latter without sacrificing the former. We will use a combination of experimental and modeling tools to study VITT emergence and progression on different scales, ranging from micro- (formation of platelet-activating immune complexes) to macroscale (thrombi formation). We have already obtained a complete amino acid sequence of the pathogenic VITT antibody and produced its recombinant copy (RVT1) in quantities sufficient for both biophysical and biological investigations. On the microscale, we will use mass spectrometry and other biophysical tools to study the architecture and biological properties of the immune complexes composed of PF4 and RVT1. On the macro-scale, we will use these complexes to study thrombi initiation and formation using in vitro models based on microfluidic devices mimicking vascular environments relevant for VITT pathogenesis (e.g., cerebral venous vasculature). Bridging the micro- and macro-scales will allow us to elucidate the detailed mechanism of VITT progression by understanding how the disease outcome is modulated by the physical and biochemical properties of its molecular triggers. It will also provide a unique opportunity to address another enigmatic feature of VITT - its frequent localization within the cerebral venous sinuses. Lastly, correlating the amino acid sequences of the pathogenic antibodies and the germline sequences for a set of VITT patients will reveal the etiology of this disease, enabling the design of effective prophylactic and monitoring strategies. The proposed research will be carried out by an interdisciplinary team comprising chemists and biophysicists (Dr. Kaltashov's lab at UMass-Amherst), hematologists and molecular biologists (Dr. Nazy's lab at McMaster University School of Medicine) and biomedical engineers (Dr. Jiménez' lab at UMass-Amherst).", "keywords": [ "Address", "Adenovirus Vector", "Adenoviruses", "Amino Acid Sequence", "Antibodies", "Antigen-Antibody Complex", "Antigens", "Architecture", "Autoantibodies", "Binding", "Biochemical", "Biological", "Biomedical Engineering", "Biophysics", "Blood", "Blood Platelets", "Blood Vessels", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccination", "Complex", "Dangerousness", "Disease", "Disease Outcome", "Disseminated Intravascular Coagulation", "Elements", "Endothelial Cells", "Endothelium", "Engineering", "Environment", "Epitopes", "Etiology", "Genetic", "Germ Lines", "Hematologist", "Idiopathic Thrombocytopenic Purpura", "Immune", "Immunity", "In Vitro", "Innate Immune Response", "Investigation", "Link", "Mass Spectrum Analysis", "Microfluidic Microchips", "Microfluidics", "Microscopic", "Modeling", "Molecular", "Monitor", "Monoclonal Antibodies", "Mutation", "N-Glycosylation Site", "Neutrophil Activation", "PF4 Gene", "Pathogenesis", "Pathogenicity", "Pathology", "Patients", "Phenotype", "Physiological", "Platelet Activation", "Polymers", "Polysaccharides", "Predisposition", "Property", "Proteins", "Recombinants", "Research", "Research Personnel", "Role", "Signal Transduction", "Stroke", "Surface", "Techniques", "Therapeutic", "Thrombocytopenia", "Thrombosis", "Thrombus", "Universities", "Vaccination", "Vaccines", "Variant", "Work", "antigen binding", "biophysical tools", "cerebral vein", "chemokine", "crosslink", "delivery vehicle", "design", "genetic predictors", "global health", "glycosylation", "hemodynamics", "immunothrombosis", "in vitro Model", "individual patient", "medical schools", "novel", "pathogen", "physical property", "preservation", "prevent", "prophylactic", "rational design", "recruit", "shear stress", "side effect", "stoichiometry", "thrombogenesis", "thrombotic", "tool", "vaccine trial", "vector vaccine", "venous sinus" ], "approved": true } }, { "type": "Grant", "id": "15713", "attributes": { "award_id": "1R01HL178459-01", "title": "Novel cysteinyl leukotriene receptor signaling in regulating cellular, and molecular events in lung inflammation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32586, "first_name": "ROYA", "last_name": "KALANTARI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-09", "end_date": "2029-02-28", "award_amount": 579309, "principal_investigator": { "id": 32587, "first_name": "Sailaja", "last_name": "Paruchuri", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 823, "ror": "", "name": "UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Cysteinyl leukotrienes (cys-LTs; LTC4, LTD4, and LTE4) play an important role in asthma, allergy, and inflammatory bowel diseases via their receptors, CysLT1R and CysLT2R. However, the role of cys-LTs in regulating the inflammatory and proliferative phenotypes of macrophages (MФ) or their role in MФ-mediated lung inflammation is not well defined. Our preliminary work revealed a previously unidentified role for CysLT1R in balancing MФs’ inflammatory potential, metabolic function, and proliferation in vitro, and a role in driving LPS- mediated lung inflammation in vivo. Based on these findings, we hypothesize that the presence of CysLT1R drives the inflammatory state of MФs and lung inflammation in response to LPS. Further, since CysLT1R and CysLT2R antagonize each other, CysLT1R may act as a molecular brake for MФ hyper-proliferation via binding to and inhibiting CysLT2R. We propose to test this hypothesis in three aims. In Aim 1, we will determine the mechanistic aspects of how CysLT1R promotes the hyper-inflammatory MФ phenotype in vitro and analyze how CysLT1R influences the resident and recruited immune population in the lung in response to acute lung injury (ALI). In Aim 2, we will elucidate how CysLT1R suppresses MФ proliferation, and metabolism, and we will explore its antagonism towards CysLT2R in deciding the MФ activation state. Finally, in Aim 3, we will determine the pathophysiological significance of myeloid CysLT1R signaling in mediating lung inflammation in murine ALI models. Further, we will explore the therapeutic potential of blocking CysLT1R using MK571/Singulair, an FDA- approved asthma drug. Although a few reports have suggested the benefits of Singulair in reducing pulmonary inflammation during LPS-ALI and COVID-19, neither the mechanistic aspects, nor its prophylaxis vs therapeutic effect on all ALI parameters, were previously addressed. The successful completion of our project will unravel the previously unknown unique roles of CysLTR in influencing MФ function and its role in lung inflammation/injury.", "keywords": [ "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Address", "Affect", "Agonist", "American", "Arachidonic Acids", "Arbitration", "Asthma", "Autocrine Communication", "Automobile Driving", "Binding", "Biology", "Biophysics", "COVID-19", "Cells", "Clinical", "Death Rate", "Disease", "Endothelium", "Equilibrium", "Event", "Exhibits", "FDA approved", "G-Protein-Coupled Receptors", "Genes", "Hypersensitivity", "Immune", "Impairment", "In Vitro", "Infection", "Inflammation", "Inflammatory", "Inflammatory Bowel Diseases", "Inflammatory Response", "Injury", "Knock-out", "Knockout Mice", "Knowledge", "Laboratories", "Leukotriene C4", "Leukotriene D4", "Leukotriene E4", "Leukotrienes", "Life", "Lipids", "LoxP-flanked allele", "Lung", "Lung Diseases", "Macrophage", "Macrophage Activation", "Mediating", "Metabolic", "Metabolism", "Modeling", "Molecular", "Morbidity - disease rate", "Mus", "Myelogenous", "Myeloid Cells", "Organ", "Outcome", "Patients", "Pharmaceutical Preparations", "Phenotype", "Play", "Pneumonia", "Population", "Positioning Attribute", "Production", "Proliferating", "Prophylactic treatment", "Pulmonary Inflammation", "Receptor Signaling", "Refractory", "Regulation", "Reporting", "Research", "Resolution", "Respiratory Failure", "Role", "Sepsis", "Signal Transduction", "Supportive care", "Testing", "Therapeutic", "Therapeutic Effect", "Tissues", "Trachea", "Urine", "Vascular Permeabilities", "Wild Type Mouse", "Work", "antagonist", "aspirate", "cecal ligation puncture", "clinical efficacy", "cysteinyl leukotriene receptor", "cysteinyl-leukotriene", "cytokine", "cytokine release syndrome", "effective therapy", "endothelial dysfunction", "experience", "experimental study", "functional outcomes", "immunogenic", "improved", "in vivo", "inhibitor", "insight", "lipid mediator", "lung injury", "mortality", "neutrophil", "novel", "novel therapeutic intervention", "novel therapeutics", "prevent", "receptor", "recruit", "response", "restraint", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "11134", "attributes": { "award_id": "2221224", "title": "Building Resilience and Engaging in Achievement through Collaborative, Holistic Programming in STEM", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "S-STEM-Schlr Sci Tech Eng&Math" ], "program_reference_codes": [], "program_officials": [ { "id": 2077, "first_name": "Connie", "last_name": "Della-Piana", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-03-15", "end_date": "2029-02-28", "award_amount": 1018320, "principal_investigator": { "id": 27119, "first_name": "Laura", "last_name": "Strausberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27117, "first_name": "Holly", "last_name": "Boettger-Tong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 27118, "first_name": "Helen", "last_name": "Carter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1989, "ror": "https://ror.org/05d7pr418", "name": "Wesleyan College", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "This project aims to answer the national need for well-educated scientists, mathematicians, engineers, and technicians by supporting the retention and graduation of high-achieving, low-income students with demonstrated financial need. Over its six-year duration, this project will fund scholarships to 21 unique full-time students who are pursuing bachelor’s degrees in biology, neuroscience, and applied mathematical science. First-year students, particularly students who attend rural high schools in the region, will receive scholarships for four years. Scholarships will begin at $6,500 in Year 1 and incrementally increase to $8,000 in Year 4 based on financial need. Additionally, students will receive summer scholarships of $2,000 during Years 2-4 for those scholars who opt to take six credits of summer courses for academic advancement or recovery. Informed by the research literature, institutional data, and student survey data, the curricular and co-curricular supports include implementation of mathematics support in early gateway STEM courses through co-requisite pre-calculus courses; a summer bridge program; development and support of mindfulness practices by scholars that include self-visualization; robust faculty mentoring; peer tutoring; micro-credentials; networking; undergraduate research experiences and internships; and placement into student cohorts. Recognizing the importance of financial support and a robust system of academic and co-curricular support and cohorts, the design of project activities and strategies respond to the impact of COVID-19 on secondary and post-secondary education. \n\nThe overall goal of this project is to increase STEM degree completion of low-income, high-achieving undergraduates with demonstrated financial need at Wesleyan College, a small liberal arts college for women. Four objectives provide a framework for the project to achieve its goal. First is the recruitment and enrollment of 21 low-income academically talented female undergraduate scholars in biology, neuroscience, and applied mathematical science. Second is the retention of 71% of the scholars in their STEM majors from their first to second year. Third is meeting a graduation target of 67% of scholars in STEM and ensuring that 79% of the graduating scholars enter into the STEM workforce or graduate studies in STEM. Fourth, and finally, is investigation into the efficacy of the proposed strategies and activities to influence student success and the influence of mindfulness practices in reducing stress overall and specifically in gateway mathematics courses. To support and inform project implementation and contribute to a deep understanding of psychosocial factors influencing student success, a mixed methods evaluation and research study will be conducted using quantitative and qualitative research methods for project improvement (formative evaluation), accountability (summative evaluation), and knowledge generation. Findings resulting from this project will be disseminated throughout the Wesleyan College community; statewide conferences for mathematics teachers; local, regional, state, and national conferences focused on curricular and co-curricular innovation (e.g., First Year Experience, undergraduate research experiences, education of women students); and research conferences on education. This project is funded by NSF’s Scholarships in Science, Technology, Engineering, and Mathematics program, which seeks to increase the number of low-income academically talented students with demonstrated financial need who earn degrees in STEM fields. It also aims to improve the education of future STEM workers, and to generate knowledge about academic success, retention, transfer, graduation, and academic/career pathways of low-income students.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7916", "attributes": { "award_id": "1IK6BX006032-01", "title": "BLRD Merit Review Research Career Scientist Award", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-04-01", "end_date": "2029-03-31", "award_amount": null, "principal_investigator": { "id": 23775, "first_name": "Shyam S", "last_name": "Mohapatra", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1638, "ror": "", "name": "JAMES A. HALEY VA MEDICAL CENTER", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1638, "ror": "", "name": "JAMES A. HALEY VA MEDICAL CENTER", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal seeks to renew Research Career Scientist Award held by Dr. Shyam S Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2007. He is a Distinguished Health Professor and the Director of the Division of Translational Medicine- Center for Research and Education in Nanobioengineering at the VA-affiliated academic center- the University of South Florida. With ~235 publications, 40 patents, an h-index of 53 and an i-index of 161, he is recognized nationally and internationally for his contributions to the field of nanoscale biomedical diagnostics and therapeutics in relation to viral infections, traumatic brain injury (TBI) and cancers. He has received substantial extramural research support including awards from the NIH, DOA, ONR, Department of Veterans’ Affairs and Florida Department of Health. He is the recipient of several international/national awards and recognitions. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 1996 and has been continuously funded with the Merit Review Award focused on respiratory syncytial virus (RSV) infection since 1999. Current and ongoing research activities to be supported by this RCS Award are as follows. Project #1. a) Develop new prophylactic, or therapeutic approaches involving broad antiviral and anti-inflammatory compounds formulated using novel nanoscale technologies, which are effective against COVID-19 and other respiratory viral infections. The currently proposed Merit Review project aims to develop a simple, smart and translatable nanoscale system that combines novel targets for antiviral- and replication and inflammation inhibitors. He currently leads two additional projects, as a multi-PI. This proposal aims to characterize novel virus-neutralizing particles that may serve as prophylaxis and/or therapy. b) Also, based on his recent experience in artificial intelligence (AI)-enhanced imaging, and preliminary data with COVID-19, he was funded by CSRD to examine the potential to clinically diagnose and prognose COVID 19 by AI-aided chest CT. Project #2. Investigate and test a novel targeted oncolytic viro-cell therapy (OVT) for lung cancer using the mesenchymal stem cell (MSCs) infected by RSV, which is harmless for immunocompetent individuals. Thus, it is planned to use a 3D multicell tumoroid and biopsy-derived cultures in vitro and mouse model of lung cancer in vivo to evaluate the safety and efficacy of OVT. The project to data has attracted industry collaboration, which might lead to clinical trials. Project #3. Investigate the potential of a novel combinatorial therapeutic approach in a mouse CCI model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by MSC therapy. VA Impact: These highly innovative applications of nanomedicine approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic, and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. The development of these effective nanotherapeutics will greatly improve the quality of Veteran’s healthcare.", "keywords": [ "2019-nCoV", "3-Dimensional", "Affect", "American", "Anti-Inflammatory Agents", "Antiviral Agents", "Artificial Intelligence", "Asthma", "Award", "Biological Assay", "Biology", "Biopsy", "Birds", "CCL20 gene", "COVID-19", "Cell Therapy", "Clinical", "Clinical Trials", "Collaborations", "Data", "Development", "Diagnostic", "Disease", "Education", "Educational process of instructing", "Elderly", "Endowment", "Extramural Activities", "Florida", "Formulation", "Funding", "Future", "General Population", "Goals", "Health", "Healthcare", "Hospitals", "Hypersensitivity", "Image Enhancement", "Immunocompetent", "Immunology", "In Vitro", "Incidence", "Individual", "Industry Collaboration", "Inflammation", "Inflammatory", "International", "Lead", "Legal patent", "Liposomes", "Malignant neoplasm of brain", "Malignant neoplasm of lung", "Medicine", "Mesenchymal Stem Cells", "Methods", "Modeling", "Mus", "Nanofiber Scaffold", "Nature", "Nerve Regeneration", "Nursing Faculty", "Oligosaccharides", "Oncolytic", "Peptides", "Phospholipids", "Pneumonia", "Property", "Prophylactic treatment", "Publications", "Reporting", "Research", "Research Activity", "Research Personnel", "Research Support", "Respiratory Syncytial Virus Infections", "Respiratory syncytial virus", "SARS-CoV-2 antiviral", "Safety", "Scientist", "Seminal", "Small Interfering RNA", "System", "Technology", "Testing", "Therapeutic", "Training", "Translations", "Traumatic Brain Injury", "United States Department of Veterans Affairs", "United States National Institutes of Health", "Universities", "Veterans", "Viral Respiratory Tract Infection", "Virus Diseases", "Work", "base", "bench to bedside", "career", "chest computed tomography", "clinical diagnosis", "clinical diagnostics", "combinatorial", "drug efficacy", "efficacy testing", "experience", "graduate student", "human disease", "improved", "in vivo", "indexing", "influenza infection", "inhibitor/antagonist", "innovation", "mouse model", "nano", "nanoformulation", "nanomedicine", "nanomicelles", "nanoscale", "nanosystems", "nanotherapeutic", "novel", "novel diagnostics", "novel therapeutics", "novel virus", "pandemic disease", "particle", "personalized cancer therapy", "prevent", "professor", "prophylactic", "respiratory infection virus", "small hairpin RNA", "stem cell therapy", "translational medicine" ], "approved": true } } ], "meta": { "pagination": { "page": 1390, "pages": 1419, "count": 14184 } } }